Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

May 28, 2015 9:12 AM ET


Company Overview of Conatus Pharmaceuticals Inc.

Company Overview

Conatus Pharmaceuticals Inc., a biotechnology company, focuses on the development and commercialization of novel medicines to treat liver diseases in the United States. Its products include Emricasan, an orally active pan-caspase protease inhibitor, which is in Phase 2 clinical trials for the treatment of liver cirrhosis, acute-on-chronic liver failure, post liver transplant clearance of hepatitis C virus infection with sustained viral response, non-alcoholic steatohepatitis, and nonalcoholic fatty liver disease. The company was founded in 2005 and is headquartered in San Diego, California.

16745 West Bernardo Drive

Suite 200

San Diego, CA 92121

United States

Founded in 2005

25 Employees



Key Executives for Conatus Pharmaceuticals Inc.

Co-Founder, Chief Executive Officer, President and Director
Age: 62
Total Annual Compensation: $460.0K
Co-Founder, Chief Scientific Officer and Executive Vice President of Research & Development
Age: 56
Total Annual Compensation: $325.6K
Executive Vice President of Clinical Development
Age: 59
Total Annual Compensation: $94.0K
Compensation as of Fiscal Year 2014.

Conatus Pharmaceuticals Inc. Key Developments

Conatus Pharmaceuticals Inc. Announces Unaudited Consolidated Financial Results for the First Quarter Ended March 31, 2015

Conatus Pharmaceuticals Inc. announced unaudited financial results for the first quarter ended March 31, 2015. For the quarter, the company reported interest income of $11,419 against $20,773 a year ago. Net loss was $5,979,664 or $0.38 per basic and diluted share against $5,243,356 or $0.34 per basic and diluted a year ago.

Conatus Pharmaceuticals Inc. to Report Q1, 2015 Results on May 07, 2015

Conatus Pharmaceuticals Inc. announced that they will report Q1, 2015 results at 4:30 PM, US Eastern Standard Time on May 07, 2015

Conatus Pharmaceuticals Inc., Q1 2015 Earnings Call, May 07, 2015

Conatus Pharmaceuticals Inc., Q1 2015 Earnings Call, May 07, 2015

Similar Private Companies By Industry

Company Name Region
Everon Biosciences, Inc. United States
Goddard Labs, Inc. United States
Provasis Therapeutics, Inc. United States
ZelleRx Corporation United States
Edge BioServ, LLC United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Conatus Pharmaceuticals Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at